+

EP1651260B2 - Lawsonia intracellularis d'origine europeenne, vaccins, agents diagnostiques et procedes d'utilisation de ceux-ci - Google Patents

Lawsonia intracellularis d'origine europeenne, vaccins, agents diagnostiques et procedes d'utilisation de ceux-ci Download PDF

Info

Publication number
EP1651260B2
EP1651260B2 EP04778282.6A EP04778282A EP1651260B2 EP 1651260 B2 EP1651260 B2 EP 1651260B2 EP 04778282 A EP04778282 A EP 04778282A EP 1651260 B2 EP1651260 B2 EP 1651260B2
Authority
EP
European Patent Office
Prior art keywords
isolate
lawsonia intracellularis
intracellularis
live
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP04778282.6A
Other languages
German (de)
English (en)
Other versions
EP1651260B1 (fr
EP1651260A1 (fr
Inventor
Michael B Roof
Jeremy J. Kroll
Jeffrey P. Knittel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health USA Inc
Original Assignee
Boehringer Ingelheim Vetmedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34115340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1651260(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Vetmedica Inc filed Critical Boehringer Ingelheim Vetmedica Inc
Priority to SI200431296T priority Critical patent/SI1651260T2/sl
Priority to PL04778282T priority patent/PL1651260T5/pl
Publication of EP1651260A1 publication Critical patent/EP1651260A1/fr
Publication of EP1651260B1 publication Critical patent/EP1651260B1/fr
Priority to CY20091101223T priority patent/CY1109652T1/el
Application granted granted Critical
Publication of EP1651260B2 publication Critical patent/EP1651260B2/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/825—Bacterial vaccine for porcine species, e.g. swine

Definitions

  • the present invention relates to live Lawsonia intracellularis vaccines and discloses methods for protecting against and diagnosing L. intracellularis infection.
  • the products and processes of the invention are attainable, in part, as the result of an improved method for cultivating large scale supplies of L. intracellularis , including both a novel isolate of L. intracellularis of European origin and a method of preparing a lyophilized product containing the attenuated European isolate as vaccine product.
  • L. intracellularis the causative agent of porcine proliferative enteropathy (“PPE"), affects virtually all animals, including: rabbits, ferrets, hamsters, fox, horses, and other animals as diverse as ostriches and emus.
  • L. intracellularis is a particularly great cause of losses in swine herds in Europe as well as in the United States.
  • a consistent feature of PPE is the occurrence of intracytoplasmic, non-membrane bound curved bacilli within enterocytes in affected portions of intestine.
  • the bacteria associated with PPE have been referred to as " Campylobacter-like organisms.”
  • the causative bacteria have been identified as a novel taxonomic genus and species, vernacularly referred to as Ileal symbiont (IS) intracellularis.
  • Ileal symbiont Ileal symbiont
  • L. intracellularis is an obligate, intracellular bacterium which cannot be cultured by normal bacteriological methods on conventional cell-free media and has been thought to require attached epithelial cells for growth.
  • S. McOrist et al., Infection and Immunity, Vol. 61, No. 19, 4286-4292 (1993 ) and G. Lawson et al., J. of Clinical Microbiology, Vol. 31, No, 5, 1136-1142 (1993 ) discuss cultivation of L. intracellularis using IEC-18 rat intestinal epithelial cell monolayers in conventional tissue culture flasks.
  • H. Stills, Infection and Immunity, Vol. 59, No. 9, 3227-3236 (1991 ) discusses using Intestine 407 human embryonic intestinal cell monolayers and GPC-16 guinea pig colonic adenocarcinoma cell monolayers in conventional tissue culture flasks.
  • L. intracellularis vaccine has been approved for use in the United States, which vaccine is based on L. intracellularis isolates described and claimed in United States Patent Nos. 5,714,375 and 5,885,823 .
  • the above-described vaccine is sold by Boehringer Ingelheim Vetmedica, Inc., 2621 North Belt Highway, St. Joseph, Missouri 64506-2002, under the trademark ENTERISOL ® Ileitis, and includes live attenuated L. intracellularis bacteria of North American origin.
  • One object of the invention is to provide an improved L. intracellularis vaccine using an isolate of European origin.
  • Another object of the invention is to provide an improved method for cultivation of L. intracellularis on a large scale and improved techniques for production of L. intracellularis vaccines.
  • the present disclosure provides a newly isolated L. intracellularis from Europe, a method of attenuating such an isolate, and the attenuated isolate thereof.
  • the present invention provides a live vaccine for the immunization of an animal, comprising a pharmaceutically effective amount of an avirulent live Lawsonia intracellularis isolate and a pharmaceutically acceptable carrier, wherein said avirulent live isolate is Lawsonia intracellularis deposit isolate ATCC No. PTA-4926 or any avirulent live Lawsonia intracellularis isolate of European origin, characterized in that said avirulent live Lawsonia intracellularis does not cause fecal shedding at day 14 post vaccination.
  • isolate DK 15540 The newly isolated L. intracellularis from Europe, isolate DK 15540, is deposit isolate ATCC accession No. PTA-4927.
  • the attenuated isolate derived from isolate DK 15540, is designated isolate B3903, ATCC accession No. PTA-4926.
  • L. intracellularis means the intracellular, curved gram-negative bacteria described in detail by C. Gebhart et al., Int'l. J. of Systemic Bacteriology, Vol. 43, No.3, 533-538 (1993 ) and S. McOrist et al., Int'1. J. of Systemic Bacteriology, Vol. 45, No.
  • the term "attenuated isolate” means any L. intracellularis isolate that is prepared according to the cultivation and passaging techniques taught herein to achieve avirulence while maintaining immunogenic properties when administered to a host animal including but not limited to the attenuated isolate designated B-3903 which was deposited under the Budapest Treaty with the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 on January 9, 2003 and assigned accession number PTA-4926.
  • the attenuated isolate can be used as an immunogen in antimicrobial vaccines for animals, including birds, fish, and mammals such as cattle, swine, horses, and primates.
  • Such vaccines can be prepared by techniques known to those skilled in the art and given the teachings contained herein.
  • Such a vaccine would comprise an immunologically effective amount of the attenuated isolate in a pharmaceutically acceptable carrier.
  • the vaccine could be administered in one or more doses.
  • An immunologically effective amount is determined by means known in the art without undue experimentation, given the teachings contained herein.
  • the amount of avirulent bacteria should be sufficient to stimulate an immune response in disease-susceptible animals while still being avirulent. This will depend upon the particular animal, bacteria, and disease involved.
  • the recommended dose to be administered to the susceptible animal is preferably about 3.0 TCID 50 (tissue culture infective dose 50% end point)/dose to about 6.0 TCID 50 /dose and more preferably about 4.0 TCID 50 /dose to about 5,0 TCID 50 /dose.
  • the titer of the vaccine is about 4.9 TCID 50 /dose as determined by Tissue Culture Infective Dose 50% endpoint dilution assay (TCID 50 ),
  • the carriers are known to those skilled in the art and include stabilizers and diluents. Such a vaccine may also contain an appropriate adjuvant.
  • the vaccines of the invention may be used in combination with other vaccines, for example, as a diluent of another vaccine.
  • the vaccine preparations may also be desiccated, for example, by freeze drying for storage purposes or for subsequent formulation into liquid vaccines.
  • the disclosure also comprises a method for inducing an immune response to virulent, wild-type L. intracellularis bacteria in an animal host for the purpose of protecting the host from such bacteria.
  • the method comprises administering an immunologically effective amount of the attenuated bacteria of the invention to the host and, preferably, administering the vaccine of the invention to the host.
  • the term "large-scale cultivation” means a level of cultivation of L. intracellularis greater than approximately 2.0 to 3.0 liters and includes production on a scale of 100 liters or more. "Cultivation” as used herein, means the process of promoting the growth, reproduction and/or proliferation of L. intracellularis .
  • L. intracellularis can be cultivated by methods known in the art, preferably, according to United States Patent Nos. 5,714,375 and 5,885,823 .
  • culture cells may first be inoculated with an inoculum comprising L. intracellularis bacteria so as to infect the cells with the bacteria.
  • Numerous cell lines can be used in practicing the invention, including, but not limited to, IEC-18 (ATCC 1589)-rat intestinal epithelial cells, HEp-2 (ATCC 23)-human epidermoid carcinoma cells, McCoys (ATCC 1696)-mouse (non-specified) cells, BGMK (Biowhittaker #71-176)-buffalo green monkey kidney cells, and swine intestinal epithelium cells.
  • the preferred culture cells are HEp-2, McCoys or IEC-18 cells.
  • the cells may be in the form of a monolayer.
  • the cells may be seeded into conventional flasks. Each flask is generally seeded with between about 1x10 5 cells to about 10x10 5 cells per 25, 75, 150, 850 cm 2 flask or roller bottle mixed with growth media.
  • the growth media may be any media for cell cultivation which includes a nitrogen source, necessary growth factors for the chosen culture cells, and a carbon source, such as glucose or lactose.
  • the preferred media is DMEM fortified with Ham's F 12 with 1-5% fetal bovine serum, although other commercially available media may be used with good results.
  • the culture cell monolayer should be at about 20 percent to about 50 percent confluency at the time of inoculation.
  • the cells should be at about 30 percent to about 40 percent confluency at the time of inoculation, most preferably at about 30 percent confluency.
  • the cells prior to being inoculated, may be grown in suspension, as described infra .
  • the cells are first grown to 100% confluency in the form of a monolayer in an adherent type system, e.g. , a roller bottle system, and then transferred to 3-3000 liters and grown in suspension.
  • the cells can be grown in suspension to the desired cell density, e.g. 2 x 10 5 cells/ml, within the 3-3000 liter vessel (bioreactor, Fermentor, spinner flask, etc.) using parameters suitable for growth within this system prior to inoculation.
  • the inoculum may be a pure culture of L. intracellularis obtained from infected swine or other animals.
  • the inoculum may be a pure culture of L. intracellularis obtained from ATCC accession No. PTA-4927.
  • the inoculum can be an intestinal homogenate prepared by scraping the mucosa off of the ileum of a swine or other animal infected with PPE.
  • ileal sections selected for culture should show severe lesions with gross thickening of the gut. Due to the fragile nature of the bacteria, samples should preferably be stored at -70°C as quickly as possible after necropsy.
  • An antibiotic to which L. intracellularis is resistant such as Vancomycin, Amphotericin B or members of the aminoglycoside group of antibiotics, including Gentamicin and Neomycin, to name a few, is preferably added to the inoculum to suppress contaminating bacteria while permitting L. intracellularis growth.
  • inoculation of the culture cells can be performed by various techniques known in the art, given the teachings herein.
  • the bacteria and/or inoculated culture cells are then incubated under a reduced dissolved O 2 . concentration. At dissolved oxygen concentrations greater than 10% L. intracellularis growth is less than optimal with cessation of growth eventually occurring at oxygen concentrations outside this range.
  • the bacteria and/or inoculated culture cells are incubated in a dissolved oxygen concentration in the range of about 0% to about 10%. More preferably, the bacteria and/or cells are incubated in an oxygen concentration in the range of about 0% to about 8%, with an oxygen concentration of about 0% to about 3.0% being most preferred.
  • the proper concentration of carbon dioxide is also important to the proper growth of L. intracellularis .
  • the carbon dioxide concentration is in the range from about 6% to about 10%, with a carbon dioxide concentration of about 8.8% being most preferred.
  • the cells are preferably incubated at a hydrogen concentration in the range from about 4% to about 10%. Most preferably, the cells are incubated in about 0 to about 8.0% O 2 , about 8.8% CO 2 , and about 4% H 2 . Nitrogen is used as a "balance" in the gas mixture containing nitrogen (96%) and hydrogen (4%) or nitrogen (80%), carbon dioxide (10%) and hydrogen (10%) for growth of this organism. Cells are preferably incubated at a nitrogen concentration in the range from about 80% to 96%. Therefore, cells are most preferably incubated in about 0 to about 8.0% O 2 , about 8.8% CO 2 about 4% H 2 and about 96% N 2 .
  • Inoculated cells may be incubated in a dual gas incubator or other gas chambers which contain the proper hydrogen, oxygen and carbon dioxide concentrations and which allow the cells to be suspended during incubation.
  • the chamber should comprise a means for maintaining the inoculated cells in suspension, and a gas monitor and supply source to supply and maintain the proper gas concentrations.
  • the incubation temperature should be in the range of from 30°C to about 45°C and is more preferably in the range of from about 36°C to about 38°C. Most preferably, the temperature is about 37°C.
  • the necessary equipment for cultivation and attenuation is readily available to those of ordinary skill in the art given the teachings herein.
  • One example of equipment suitable for carrying out the present invention is a dual gas incubator, e.g.
  • model 480 (Lab-Line, Melrose Park, IL) in conjunction with spinner flasks to maintain the cells in suspension.
  • the presently preferred equipment comprises a fermentor, bioreactor, stir plate or rotary shaker containing at least about 2 liters media and capable of maintaining the culture cells in suspension via sparging gas of the appropriate concentration, or other means of mechanical agitation, and continuously monitoring dissolved O 2 levels in the media. New Brunswick, Braun and other companies make suitable fermentors and bioreactors for this purpose.
  • the culture cells can be agitated and maintained in suspension by a variety of methods known in the art including, for example, culture flasks, roller bottles, membrane cultures, biobags, WAVETM bioreactor systems, fermentors and spinner flasks.
  • the cells may be kept in suspension during incubation by incubating the cells in a spinner flask inside a dual gas incubator or similar apparatus
  • spinner flask means a flask or other container which employs a paddle, propeller or other means to agitate the culture and keep the cells contained therein in suspension.
  • the inoculated cells are incubated until the cells reach confluency and then the cells are placed in a spinner flask containing growth media and incubated in a dual gas incubator while spinning the flask.
  • the inoculated cells are scraped or trypsinized and passaged into the spinner flask. This can be achieved by a variety of methods known in the art such as using a cell scraper to detach the cells.
  • the paddle of the spinner flask is typically rotated in the range of from about 5 to about 500 rpm on a magnetic stir plate in order to maintain the infected cells in suspension.
  • a portion of the cultivated L. intracellularis is then passaged to fresh culture to increase the production of L. intracellularis bacteria.
  • the term "passaging” or variations thereof herein means the process of transferring a portion of the cultivated L. intracellularis to fresh culture cells in order to infect the fresh cells with the bacterium.
  • fresh means cells which have not yet been infected by L. intracellularis . Preferably such cells are on the average no more than approximately one day old.
  • the passage of L. intracellularis in suspension cultures may be accomplished by removing a portion of the original culture and adding it to a new flask containing fresh culture cells. If the original culture has a high number of bacteria/ml, for example, greater than about 10 4 bacteria/ml, it is preferable to add between about 1 to 10% (volume to volume) of culture from the infected flask to a new flask containing fresh cells. This is preferably done when 50-100% of the cells are infected. If fewer than 50% of the cells are infected, passaging is preferably accomplished by splitting the culture 1:2 into a new flask and scaling-up the volume by adding fresh tissue culture cells and media. In either case, cell lysis and other steps are not required, in direct contrast to the passage of monolayer cultures, as in the prior art.
  • At least a portion of the cultivated L. intracellularis bacteria is then harvested.
  • Harvesting is typically performed at cell infectivity of about 60% or higher; however, one skilled in the art knows that harvesting could be performed at a cell infectivity of less than 60%.
  • the harvesting step may be performed by separating the bacteria from the suspension by various techniques known to those of ordinary skill in the art, given the teachings herein.
  • intracellularis bacteria is harvested by centrifuging the contents of all or a portion of the suspension to pellet the culture cells, resuspending the resulting cell pellets, and lysing the infected cells. Typically, at least a portion of the contents is centrifuged at about 3000xg for about 20 minutes in order to pellet the cells and bacteria. The pellet may then be resuspended in, for example, a sucrose-phosphate-glutamate (SPG) solution and passed approximately 20 times through a 25 gauge needle in order to lyse the cells.
  • SPG sucrose-phosphate-glutamate
  • the samples can be centrifuged at about 145xg for about five minutes to remove cellular nuclei and debris, The supernatant may then be centrifuged at about 3000xg for about twenty minutes and the resulting pellet resuspended in an appropriate diluent, such as SPG with fetal bovine serum (to prepare harvested bacteria suitable for lyophilization, freezing, or use as an inoculant) or growth media (to prepare harvested bacteria more suitable for passaging to fresh cells).
  • an appropriate diluent such as SPG with fetal bovine serum (to prepare harvested bacteria suitable for lyophilization, freezing, or use as an inoculant) or growth media (to prepare harvested bacteria more suitable for passaging to fresh cells).
  • L. intracellularis for large-scale production is enhanced by keeping the tissue cells actively growing. With monolayers, when cultures become confluent, the rate of cell division decreases substantially. Attempts to grow L. intracellularis on monolayer tissue cultures have had limited success and scale-up has not been possible. However, using suspension cultures greatly facilitates keeping the cells actively growing and permits continuous culture expansion and scale-up. Using a fermentor and between about 0 to 3% dissolved O 2 as explained above, enables growth of up to and greater than 10 8 bacteria/ml.
  • HEp-2 cells When using IEC-18 cells, it is preferable to add gelatin, agarose, collagen, acrylamide or silica beads, such as Cultisphere-G porous microcarriers (HyClone Laboratories, Logan Utah), along with the growth media.
  • HEp-2 cells and others do not require microcarriers according to the methods used herein.
  • HEp-2 cultures For culture maintenance purposes, with HEp-2 cultures, preferably 25% to 50% of the culture is removed and replaced with fresh media at weekly intervals. For cell cultures with microcarriers or beads, preferably 25% to 50% of the culture is removed and replaced with fresh media 1-2 times weekly. For scale-up purposes, an additional 25% to 50% of media, or media with microcarriers, may be added to the culture.
  • passage to fresh cells generally occurs between about every 2 to about 7 days. Assuming that the culture cells become at least 70% infected within 2 to 7 days, preferably passage occurs between about every 5 to 7 days.
  • the present invention provides vaccines comprising an effective amount of an avirulent live Lawsonia intracellularis isolate as specified in the claims and methods for producing such vaccines against a novel isolate of L. intracellularis of European origin.
  • a novel isolate of L. intracellularis of European origin Preferably, after maintaining the infected cells in suspension for an extended time (for example, 6-8 months), at least a portion of the cultivated L. intracellularis bacteria are harvested and monitored for potential attenuation. Such monitoring is preferably accomplished by host animal or animal model challenges to select for an attenuated isolate.
  • Such attenuated isolates are used in vaccines according to the methods taught herein.
  • the present invention allows rapid culture expansion, an increase in yields of 100-1000 fold, and reduced cost for production of L. intracellularis of European origin.
  • L. intracellularis of European origin As a result, the abundant supply of L. intracellularis bacteria produced is readily attenuated for vaccine production purposes.
  • the method of growing L. intracellularis in suspension greatly increases the ease, speed, and number of bacterium available for this purpose. The more cells and cell divisions which occur, the greater the level of mutations occurring which are advantageous in vaccine development.
  • growth in suspensions increases the expression of important immunogens controlled by environmentally regulated genes and their expression products.
  • the resulting attenuated isolates can be cultivated in tissue culture monolayers but are preferably cultivated in suspension cultures. By multiple passage, an attenuated L. intracellularis is produced and selected for vaccine preparation.
  • the resulting attenuated isolate is ATCC accession No. PTA-4926.
  • the vaccine antigen can be harvested by centrifugation or microfiltration as described above. The antigen is then standardized at a defined level based on the optimum host animal immune response, determined by a dose titration in the host animal species.
  • the bacteria are serially passaged to induce and select for an attenuated, avirulent live culture.
  • the culture is tested in the host animal for signs of attenuation.
  • the culture is harvested as described earlier and lyophilized.
  • Swine for example, are orally vaccinated with 1x10 4 to 1x10 6 bacteria.
  • the swine are orally inoculated with about 1x10 7 organisms from a less passaged (less than 30 passages in vitro past the original isolation from the intestinal homogenate) virulent culture of L. intracellularis .
  • Infected animals are necropsied 21 days after challenge and the small intestines observed for gross lesions as well as microscopic lesions.
  • PCR indirect fluorescent antibody
  • IHC immunohistochemistry
  • an attenuated immunogenic L. intracellularis isolate is produced after continuous culture for about 150 days to about 250 days, during which time the culture is passaged about 50-100 times.
  • an attenuated immunogenic L. intracellularis isolate is produced after continuous culture for about 150 days to about 250 days, during which time the culture is passaged about 50-100 times.
  • other attenuated cultures may be produced by varying these figures.
  • the vaccine product of the invention can be lyophilized. After harvesting, the isolate can be concentrated by various methods known in the art and can be mixed with a stabilizer, e.g. sucrose gelatin stabilizer. The vaccine product can then be subjected to freezing and drying (lyophilization). Generally, the freezing step comprises ramping to about -45°C ⁇ 3°C and holding for about 150 minutes to about 480 minutes.
  • the drying step can comprise primary and secondary drying steps.
  • the primary drying step can comprise: (a) ramping to between about -30°C to about -5°C and holding for between about 120 minutes to about 1000 minutes, and, optionally (b) ramping to between about-5°C to about 5°C and holding for between about 150 minutes to about 2000 minutes.
  • the secondary step generally comprises ramping to about 27°C ⁇ 5°C and holding for between about 330 minutes to about 1120 minutes, One skilled in the art knows that these ranges can be adjusted depending on conditions, e.g. , starting volume,
  • a vaccine is then prepared comprising an immunologically effective amount of the attenuated L. intracellularis in a pharmaceutically acceptable carrier.
  • a vaccine comprises ATCC accession No. PTA-4926 in a pharmaceutically acceptable carrier.
  • the combined immunogen and carrier may be an aqueous solution, emulsion or suspension.
  • An immunologically effective amount is determinable by means known in the art without undue experimentation given the teachings contained herein.
  • the quantity of immunogen will be between 5 and 5000 micrograms, and between 10 2.0 and 10 9.0 TCID 50 , preferably between 10 3.0 and 10 6.0 TCID 50 , more preferably between 10 4.0 and 10 5.0 TCID 50 , when purified bacteria are used.
  • the present invention also encompasses combination vaccines comprising the attenuated L. intracellularis isolate designated ATCC accession No. PTA-4926 and antigenic material from at least one other pathogen, including but not limited to: Salmonella spp. (e.g., Salmonella choleraesuis, Salmonella typhimurium ), Erysipelothrix spp. (e.g., Erysipelothrix rhusiopathiae ), Haemophilus spp. (e.g., Haemophilus parasuis ), Mycoplasma spp.
  • Salmonella spp. e.g., Salmonella choleraesuis, Salmonella typhimurium
  • Erysipelothrix spp. e.g., Erysipelothrix rhusiopathiae
  • Haemophilus spp. e.g., Haemophilus parasuis
  • Clostridium spp (e.g., Clostridium perfingens, Clostridium difficile ), Streptococcus spp. (e.g., Streptococcus suis ), Brachyspira spp. (e.g., Brachyspira hyodysenteriae ), Bordetella (e.g., Bordetella bronchiseptica ), Pasteurella spp.
  • circovirus e.g., porcine circovirus type 2
  • porcine reproductive and respiratory syndrome PRRS
  • SIV porcine reproductive and respiratory syndrome
  • coronovirus e.g., transmissible gastro-enteritis (TGE) virus, porcine respiratory corona virus
  • parvovirus or Escherichia coli
  • Escherichia coli e.g., Pasteurella multocida
  • circovirus e.g., porcine circovirus type 2
  • PRRS porcine reproductive and respiratory syndrome
  • SIV swine influenza virus
  • coronovirus e.g., transmissible gastro-enteritis (TGE) virus, porcine respiratory corona virus
  • parvovirus e.g., or Escherichia coli
  • the combination vaccine comprises the attenuated L. intracellularis isolate designated ATCC accession No. PTA-4926 and antigenic material from Salmonella choleraesuis, Erysipelothrix spp. Clostridium spp, Brachyspira spp., transmissible gastro-enteritis (TGE) virus, and Escherichia coli ; and a pharmaceutically acceptable carrier.
  • Antigenic material from Clostridium spp. can include, but is not limited to, Clostridium perfingens and Clostridium difficil.
  • Antigenic material from Erysipelothrix spp can include, but is not limited to, Erysipelothrix rhusiopathiae.
  • the combination vaccine comprises the attenuated L. intracellularis isolate designated ATCC accession No. PTA-4926 and antigenic material from Salmonella choleraesuis and Erysipelothrix spp.; and a pharmaceutically acceptable carrier.
  • the combination vaccine comprises the attenuated L. intracellularis isolate designated ATCC accession No. PTA-4926 and antigenic material from Salmonella choleraesuis and Erysipelothrix rhusiopathiae ; and a pharmaceutically acceptable carrier.
  • the combination vaccine comprises the attenuated L. intracellularis isolate designated ATCC accession No. PTA-4926 and antigenic material from at least one other pathogen, including but not limited to: Clostridium spp. (e.g., Clostridium tetani ), equine influenza virus (EIV) (e.g., EIV-1, EIV-2), equine herpes virus (EHV) (e.g., EHV-1, EHV-2, EHV-3, EHV-4, EHV-5, EHV-6, EHV-7,), alphavirus (e.g., eastern encephalitis virus, western encephalitis virus, Venezuelan encephalitis virus), or West Nile virus; and a pharmaceutically acceptable carrier.
  • Clostridium spp. e.g., Clostridium tetani
  • EIV equine influenza virus
  • EHV equine herpes virus
  • alphavirus e.g., eastern
  • the vaccines according to the invention are generally administered to susceptible animals, preferably swine, in one or more doses.
  • the live vaccine may be administered 1 or 2 times at 2 week intervals.
  • one dose is preferred.
  • the preferred routes of administration of attenuated live isolates are intramuscular, oral or intranasal.
  • the L. intracellularis bacteria of European origin of the instant disclosure can be used as an antigen in an ELISA or other immunoassay, such as an immunofluorescent antibody test ("IFA"), to detect antibodies to L. intracellularis in the serum and other body fluids of animals suspected of being infected with the bacteria.
  • IFA immunofluorescent antibody test
  • the presently preferred immunoassay is an IFA as described in the example below.
  • the bacteria of the instant invention can be used in a Western Blot assay.
  • the preferred ELISA protocol according to the invention is as follows:
  • the preferred Western Blot protocol is as follows:
  • the L. intracellularis bacteria of European origin of the instant disclosure, or components derived from such bacteria can also be used to prepare antiserum or antibodies for diagnostic, prophylactic, or therapeutic use.
  • the L. intracellularis bacteria of European origin of the instant disclosure, or components derived from such bacteria can be administered to a non-human animal in an amount effective to elicit an immune response and the antiserum or plasma containing antibodies to the L. intracellularis bacteria, or components derived from such bacteria, can be collected according to methods known in the art and described herein.
  • DK 15540 L. intracellularis virulent isolate DK 15540 (DK 15540, DK-15540 and 15540 are used interchangeably herein) was isolated by the University of Minnesota from an ileal homogenate of a Danish pig infected with acute porcine hemorrhagic enteropathy. This isolate has been deposited under the Budapest Treaty with the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 on January 9, 2003 and assigned accession number PTA-4927. The isolation process included scraping the mucosa from the ileum, homogenizing, trypsinizing for 30 minutes, and passing through a tissue grinder.
  • the ileal homogenate was then passed through a series of filters consisting of 5.0, 1.0, and 0.65 ⁇ m, The homogenate was diluted in sucrose phosphate glutamate buffer with 10% fetal bovine serum (FBS). Aliquots (6x1ml) of homogenate were made and stored at less than -70°C. The homogenate was used as inoculum to infect T-75 cm 2 flasks of McCoy cells. Cultures were monitored daily for McCoy cell infection by scraping McCoy cell monolayers, lysing cells by potassium chloride treatment, and placing the concentrated cell pellet on microscope slides stained by IFA using monoclonal antibodies specific for L. intracellularis .
  • FBS fetal bovine serum
  • MCS EU McCoy Master Cell Stock
  • DMEM/F12 Dulbecco's Modified Eagle Medium with Ham's Fortified F 12
  • NBS newborn bovine serum
  • FBS fetal bovine serum
  • Master and Working Seed were stored in DMEM/F12 with 1-10% (v/v) NBS or FBS and 5-15% (v/v) glycerol (master and working seed storage media).
  • sucrose gelatin stabilizer SGS (final product storage media).
  • L. intracellularis seed and production organisms were grown in McCoy Master Cell Stock (ATCC accession number CRL 1696, batch number F-10422).
  • the mast cell stock was identified as 3894MMCSS at passage X.
  • the master cell stock was passaged an additional six times and identified as EU McCoy MCS X+0.
  • EU McCoy MCS passage X+0 was stored at -70°C ⁇ 5°C or colder.
  • Production vaccine was made in EU McCoy MCS cell line subcultures through the 40 th passage.
  • EU McCoy MCS were propagated in tissue culture flasks with 25-150 cm 2 surface area, Costar cell cubes, in roller bottles with 850 cm 2 to 2, 2250 cm 2 , in spinner flasks up to 40L capacity, and in bioreactors having 3L to 500L capacity.
  • Seed cultures of L. intracellularis were grown in 250-40,000ml spinner flasks, 850 cm 2 to 2,250 cm 2 roller bottles, tissue culture flasks with 25-150 cm 2 surface area, or in bioreactors having 3L to 500L capacity.
  • Production cultures of L. intracellularis were grown in 6L to 40L spinner flasks or in bioreactors having 3L to 500L capacity.
  • the cultures were incubated at 37°C ⁇ 2°C for 3 to 10 days in a reduced oxygen atmosphere with agitation to maintain the suspension. Additional medium and/or McCoy cells can be added to continue the growth process.
  • Cultures were examined for signs of adequate bacterial growth by indirect fluorescent antibody (IFA) staining. Cultures that were ready for harvest exemplified 60 to 100% cell infectivity. Percent infectivity was determined by observation of at least three fields, each field containing enough McCoy cells to fill at least 80% of the area. To be considered infected, approximately 50% of the cell is filled with bacteria.
  • IFA indirect fluorescent antibody
  • Production cultures exhibited at least 4.9 TCID 50 /ml by IFA staining and were free of any evidence of contamination upon microscopic observation.
  • the vaccine product can be concentrated by various methods, e.g. , by allowing the culture to settle with subsequent decanting of the supernatant, by membrane filtration (0.22 ⁇ m or smaller), perfusion, or by centrifugation.
  • Hydrolyzed gelatin solution is prepared by mixing gelatin with deionized water or water for injection at approximately 25% final total volume of SGS batch size and hydrolyzing in an autoclave for 120 minutes at 121°C.
  • the hydrolyzed gelatin solution (40.0 g/L) was then mixed with deionized water or water for injection at approximately 75% final total volume of SGS batch size.
  • Potassium hydroxide (AR) (0.548 g/L), L-glutamic acid (1.440 g/L), dipotassium phosphate (AR) (2.508 g/L), potassium dihydrogen phosphate (AR) (1.030 g/L), and sucrose (AR) (150.00 g/L) were added and the solution was thoroughly mixed.
  • the pH of the stabilizer was then adjusted to 6.8 to 7.0 with hydrochloric acid or sodium hydroxide solutions.
  • Deionized water or water for injection was added to 100% of desired final volume of the SGS. The complete stabilizer was thoroughly mixed, and the entire solution was sterilized by filtration through a 0.1 micron filter.
  • Table 1 Example of Assembly of Units to Make a Serial is shown in Table 1: Table 1 L. intracellularis 200,000-300,000 ml sucrose gelatin stabilizer (SGS) 100,000 ml (25% v/v) DMEM/F12 (May be added to standardize the product) 0-150,000 ml TOTAL VOLUME 400,000 ml Volume of an average serial was 50L to 500L.
  • SGS sucrose gelatin stabilizer
  • DMEM/F12 May be added to standardize the product
  • 0-150,000 ml TOTAL VOLUME 400,000 ml Volume of an average serial was 50L to 500L.
  • the vaccine product was lyophilized according to the procedure outlined in Table 2 for a 10 dose cycle (6.0 ml fill) or Table 3 for a 50/100 dose cycle (10.0 ml fill).
  • Table 2 STEPS °C Rate (minutes) Hold (minutes) Pressure (mT) PRE-COOL* 5° Na Na Atm FREEZE -47° ⁇ 3° As fast as possible 150 Atm 1° DRYING, 1st -15° ⁇ 2° 120 120 100-150 1° DRYING, 2nd 0° ⁇ 2° 120 180 100-150 2° DRYING, 1 st 32° ⁇ 2° 240 180 60-80 2° DRYING, 2nd 26° ⁇ 2° 240 As fast as possible 60-80 Total Time: 1352 minutes (22.5 hrs) *Shelves are pre-cooled to 5°C ⁇ 2°C during the loading of the lyophilizer.
  • the objectives of this study were two-fold.
  • the first objective of this study was to observe and compare the incidence of disease caused by three different low passage isolates (two of U.S. origin and one of European origin) of L. intracellularis in pigs at 6 1 ⁇ 2 weeks of age.
  • the second objective was to observe the safety of two high passage isolates (both of European origin) of L. intracellularis in pigs at 6 1 ⁇ 2 weeks of age.
  • TCID 50 was performed on all pooled challenge isolates at the time of challenge (day 0).
  • Group 1 (10 pigs, 6 1 ⁇ 2 weeks of age) received one 10ml or equivalent intragastric (IG) dose of L. intracellularis low passage U.S. isolate N343.
  • Group 2 (10 pigs, 6 1 ⁇ 2 weeks of age) received one 10ml or equivalent IG dose of L. intracellularis low passage U.S. isolate N101494.
  • Group 3 (10 pigs, 6 1 ⁇ 2 weeks of age) received one 10ml or equivalent IG dose of L. intracellularis low passage EU isolate DK15540 p20.
  • Group 4 (10 pigs, 6 1 ⁇ 2 weeks of age) received one 10ml or equivalent IG dose of L.
  • Group 5 (20 pigs, 6 weeks of age) received one 10ml or equivalent dose of L. intracellularis high passage EU isolate DK 15540 p80.
  • Group 6 (10 pigs, 6 1 ⁇ 2 weeks of age) designated as "Strict Controls" did not receive a treatment.
  • ADWG Average Daily Weight Gains
  • Average daily weight gains were calculated from the time of challenge (day 0) to the termination of the study (day 21).
  • the average weight gain per day for the strict control group was 0.9 pounds.
  • the average weight gain for the low passage treatment groups was only 0.6 (N343), 0.8 (N101494), and 0.86 (DK15540 p20) pounds/day.
  • the high passage treatment groups revealed the same or increased average weight gain per day compared to the strict control group that didn't receive challenge with 0.9 pounds/day (DK15540 p60) and 1.05 pounds/day (DK15540 p80) respectively.
  • the mean difference in average daily weight gains was significantly lower in the N343 treatment group compared to higher passage treatment groups (DK15540 p60 and p80) and strict control group at day 21 of the study. (Pearson Chi-square p ⁇ 0.05).
  • Seroconversion to Lawsonia exposure in pigs was measured by testing for the presence of anti-Lawsonia antibodies using an IFAT assay. On day 0, only the N343 treatment group observed detectable seroconversion in 2/10 pigs. Day 7 observed 2/9 pigs (N343) and 1/10 pigs (DK15540 p20) IFA positive for Lawsonia antibodies. On day 14, 2/9 pigs were IFA positive in N343 treatment group, 1/10 in DK15540 p20 and p60 respectively.
  • Day 21 revealed 1/10 pigs (N343), 4/10 pigs (N101494) and 6/10 pigs (DK15540 p20) were IFA positive while high passage treatment groups (DK15540 p60 and p80) show no detectable seroconversion. Seroconversion to Lawsonia exposure increased in treatment groups receiving low passage L. intracellularis of both the U.S. and EU isolates day 21 of the study.
  • PCR testing of the feces demonstrated shedding of L. intracellularis beginning on day 14 where 4/ 9 in the N343, 4/10 in the N101494, and 5/10 in the DK15540 p20 low passage animals tested positive. Both high passage treatment and strict control groups were PCR negative for day 14. On day 21, DK15540 p20 treatment group had 1 animal PCR positive while all other treatment and control groups were PCR negative. No evidence of shedding was observed in high passage isolate groups (DK15540 p60 and p80) using PCR throughout the study.
  • PCR testing of mucosal scrapings from ileums and colons was performed after necropsy (day 21). Samples that were PCR positive for L. intracellularis colonization were (2/10 colons) in N101494 and (2/10 ileums, and 4/10 colons) in DK 15540 p20 low passage isolate groups. All other treatment and control groups were PCR negative in tissues day 21 of the study. Results indicated ileums and colons of pigs in DK15540 p20 were significantly more colonized with L. intracellularis compared to all treatment and control groups (*Pearson Chi-square p ⁇ 0.05).
  • Sections of the terminal ileum and colon were collected at necropsy (day 21) and placed in buffered formalin for histological analysis. Presence of intracellular bacteria and crypt hyperplasia was observed in tissues stained with Hematoxylin and Eosin (H&E) and Warthin-Starry silver reagents of 4/9 pigs (N343), 3/10 pigs (N101494), 2/10 pigs (DK15540 p60) and 1/20 pigs (DK15540 p80).
  • H&E Hematoxylin and Eosin
  • Warthin-Starry silver reagents 4/9 pigs (N343), 3/10 pigs (N101494), 2/10 pigs (DK15540 p60) and 1/20 pigs (DK15540 p80).
  • Ileums and colons were scored at the time of necropsy (day 21) for lesions associated with PPE. Tissues were given a score of 1 for normal appearance (no lesion development), a score of 2 for lesions demonstrating mild thickening, 3 for moderate thickening, and a score of 4 for severe thickening. Strict controls had an average clinical score of 1.05, N343 (1.0), N101494 (1.2), DK15540 p20 (1.2), and DK15540 p60 and p80 (1.0). Average gross lesion scores indicated no statistical difference between control and treatment groups using ANOVA test for multiple comparisons.
  • the objectives of this study were to determine the minimal protective titer of a vaccine comprising isolate B3903 (lyophilized) (DK 15540, passage 80) ("B3903 (Lyophilized) vaccine” and "B3903 vaccine” are used interchangeably herein) administered by oral drench in pigs 3 weeks of age and to demonstrate efficacy against a virulent heterologous pure culture challenge with low passage L. intracellularis , the causative agent of Porcine Proliferative Enteropathy (PPE) in swine.
  • B3903 (lyophilized) vaccine and "B3903 vaccine” are used interchangeably herein
  • DK 15540 isolates were grown continuously for 80 weeks after isolation in McCoy cell suspension. All cultures were harvested via centrifugation at 10,000 RPM for 15 minutes. The McCoy cell culture pellets containing Lawsonia were resuspended in Sucrose-Phosphate-Glutamine (SPG) solution with 10% FBS. Desiccation was performed as described in Example 1, supra. The lyophilized product is reconstituted in water, q.s. ad 2.0 ml, for injections.
  • SPG Sucrose-Phosphate-Glutamine
  • the vaccine was stored at 2°C-8°C until ready for use. After resuspension, the vaccine was stored on ice until administration.
  • a placebo consisting of uninfected McCoy tissue culture cells suspended in DMEM/F12 growth medium fortified with 5% NBS was given to treatment Groups 4 (challenge control) and 5 (negative control) on day 0 of the study. This substance was administered to piglets in treatment Group 4 by direct oral drench and given 1 x 2mL of placebo per test animal.
  • L. intracellularis N101494 was obtained from the intestines of a 12 week old pig from an Indiana farm (Unites States Patent 5,714,375).
  • L. intracellularis challenge material was grown continuously in McCoy cell suspension no more than 30 passes after initial isolation from infected gut tissue. Active cultures (2 x 3L) identified as SF 1422 and SF 1423 in addition to (1L) SF 1421 were grown in McCoy ceil suspension for 7 days to 15-30% McCoy cell infection. On the day of challenge (day 21), active cultures were harvested via centrifugation at 10,000 RPM for 15 minutes and cell pellets resuspended in 350mls total volume with SPG stabilizer. Harvested active culture was pooled with 300mLs of frozen 10X to 20X concentrated challenge stocks of low passage N101494 at various passages (pass 24 to 27 post isolation).
  • Results from the TCID 50 assay verified the amount of live L. intracellularis administered to each test animal per dose during vaccination and challenge.
  • treatment Group 1 (15 pigs) received a 2mL dose (6.0 logs/dose) of B3903 vaccine by direct oral drench.
  • treatment Group 2 (15 pigs) received 1 x 2mL dose of B3903 vaccine titrated at 4.9 logs/dose by direct oral drench.
  • treatment Group 3 (15 pigs) received 1 x 2mL dose of B3903 vaccine titrated at 3.8 logs/dose by direct oral drench.
  • test pigs in treatment Groups 1-4 received 1 x 10mL dose of virulent low passage pure culture L. intracellularis heterologous isolate N101494 by gastric gavage.
  • Group ID Average Gross Lesion Scores (ileum) Average Gross Lesion Scores (colon) Average Micro-Lesion scores (ileum) Average Micro-Lesion Scores (colon) 1 15 B3903 vaccine high dose (6.0) 1.5 ab 1.2 a 0.2 ab 0.1 a 2 15 B3903 vaccine medium dose (4.9) 1.2 ab 1.0 a 0.4 ab 0.0 a 3 15 B3903 vaccine low dose (3.8) 2.5 b 1.5 b 1.0 b 0.3 a 4 10 Challenge Controls 3.6 c 2.2 b 2.4 c 1.5 b 5 10 Strict Controls 1.0 a 1.0 a 0.0 a 0.0 a *Like letters indicate no significant difference (p ⁇ 0.05)
  • Clinical scores were recorded for each animal daily from day of challenge (day 21) to necropsy (day 42). Clinical scores were calculated to obtain an average daily clinical score reflecting the severity and duration of sickness among treatment groups due to receiving a virulent challenge of L. intracellularis. Average clinical scores for each treatment group are summarized in Table 8. Table 8 Treatment Group Group Identification Average Clinical Score 1 B3903 vaccine - high dose 3.1 a 2 B3903 vaccine - medium dose 3.0 a 3 B3903 vaccine - low dose 3.0 a 4 Challenge Control 3.0 a 5 Strict Control 3.0 a *Like letters denote no significant differences among average clinical scores from the day of challenge to necropsy (p ⁇ 0.05).
  • ADWG Average daily weight gains
  • Serum samples were collected weekly from all test animals in each treatment group and tested for presence of anti-Lawsonia IgG antibodies on days 0, 7, 14, 21, 28, 35, and 42 of the study. Positive and negative IFAT control samples were 100% accurate in all assays performed in this study. On days 0 through 21 (3 weeks post vaccination), all test animals in each treatment group were IFA negative. On day 28 (1 week post challenge) of the study, 1/15 (6.7%) test animals in the vaccine-high dose treatment group were IFA positive while all others tested IFA negative. On day 35 (2 weeks post challenge) of the study, 4/15 (26.7%) pigs in the vaccine-high dose and medium dose treatment groups and 1/10 (10%) pigs in the non-vaccine, challenge control treatment group were IFA positive for Lawsonia antibodies.
  • Both vaccine-low dose and strict control treatment groups were IFA negative on day 35.
  • 8/10 (80%) pigs in the challenge control group, 6/15 (40%) pigs in the vaccine-medium dose group, 5/15 (33.3%) pigs in the vaccine-low dose group, and 3/15 (20%) pigs in the vaccine-high dose group were IFA positive.
  • the strict control treatment group was IFA negative at study termination (day 42).
  • Seroconversion data was analyzed using the Chi-square statistic. For results obtained in the strict control treatment group, a chi-square statistic was not computed due to the 100% negative responses found for each test animal throughout the study. In treatment groups receiving a vaccine or placebo, IFAT results were compared using Chi-square statistic with an estimation of exact p-value (Monte-Carlo). Positive IFAT results obtained from challenge groups receiving a virulent pure culture challenge were significantly higher than those receiving vaccine-high dose and vaccine-low dose (p ⁇ 0.05) at day 42 (3 weeks post challenge) of the study.
  • Fecal swabs were collected weekly from all test animals in each treatment group and tested for the presence of L. intracellularis by PCR on days 0, 7, 14, 21, 28, 35, and 42 of the study. Positive and negative DNA extraction and PCR reaction controls were 100% accurate for each assay conducted in this study. All test animals in each treatment group were fecal PCR negative for L. intracellularis from day 0 (vaccination) to day 21 (challenge). Pigs in the strict control group remained fecal PCR negative for L. intracellularis in their feces throughout the study. Fecal shedding of L. intracellularis (fecal PCR positive) was evident in various treatment groups each week after challenge inoculation. These results are summarized in Table 10.
  • Ileitis PCR testing of mucosal scrapings of the terminal ileum revealed 4/10 (40%) pigs in the challenge controls, 4/15 (26.7%) pigs in the vaccine-low dose group, 2/15 (13.3%) pigs in the vaccine-medium dose group, and 1/15 (6.7%) pigs in the vaccine-high dose group PCR positive for L. intracellularis colonization.
  • Ileitis PCR testing of the colon revealed 3/10 (30%) pigs in the challenge controls, 5/15 (33.3%) pigs in the vaccine-low dose group, 1/15 (6.7%) pigs in the vaccine-medium dose group, and 2/15 (13.3%) pigs in the vaccine-high dose group PCR positive for L. intracellularis colonization. No evidence of L. intracellularis colonization was seen in tissues of the strict control group.
  • Sections 2 to 4cm in length of tonsil, mesenteric lymph node, terminal ileum, and colon were collected at necropsy (day 42) and placed in 10% buffered formalin for histological analysis. Lawsonia intracellularis was not detected by IHC staining of tonsil sections in all treatment groups at necropsy. The strict control group was negative for L. intracellularis by IHC in all tissue samples taken at necropsy. Presence of L.
  • intracellularis and microscopic lesions associated with PPE were found in the ileums of 9/10 (90%) pigs of the non-vaccinated, challenge controls, 6/15 (40%) pigs of the vaccine-low dose group, 3/15 (20%) pigs of the vaccine-medium dose group, and 1/15 (6.7%) pigs of the vaccine-high dose group respectively.
  • Microscopic lesions were evident in the colon of 8/10 (80%) pigs in the challenge control group, 3/15 (20%) pigs in the vaccine-low dose group, and 1/15 (6.7%) pigs in the vaccine-high dose group.
  • the vaccine group receiving a medium dose was IHC negative for L. intracellularis in the colon.
  • test animals were scored at the time of necropsy (day 42) for gross lesions associated with PPE.
  • Tissues from test pigs in the strict control were normal, did not contain lesions, and received average lesion scores of 1.1 (ileum) and 1.0 (colon).
  • Tissues of test animals in the non-vaccinated, challenge control group received the highest average gross lesion score for the ileum (3.6) and colon (2.0) among treatment groups.
  • Test pigs in the vaccine-low dose group received average gross lesion scores of 2.5 (ileum) and 1.5 (colon).
  • Vaccine-medium dose test pigs received average gross lesion scores of 1.5 (ileum) and 1.0 (colon).
  • Tissues of the vaccine-high dose group received average gross lesion scores of 1.5 (ileum) and 1.2 (colon).
  • Average gross lesion scores indicated evidence of a significant difference between ileums in non-vaccinated, challenge control group and vaccine-medium and high dose groups respectively (p ⁇ 0.001). Evidence of a significant difference was observed among average gross ileum scores of the challenge control compared to the vaccine-low dose group (p ⁇ 0.01). Average gross lesion scores of the colon were significantly higher in the challenge control group compared to the vaccine-medium and high dose groups respectively (p ⁇ 0.05). In addition, significant gross lesion development was observed in the ileum of the vaccine-low dose group compared to the strict control group (p ⁇ 0.001). No evidence of a statistical significance in average gross lesion scores (ileum and colon) were evident in vaccine-medium and high dose groups compared to the strict control treatment group.
  • the data from this study demonstrated that: (1) the minimum protective titer of a single oral administration of B3903 (Lyophilized) vaccine to 3 week old pigs is 4.9 logs/dose; (2) B3903 (Lyophilized) vaccine is efficacious against a virulent low passage pure culture L. intracellularis , heterologous isolate N101494; and (3) B3903 (Lyophilized) vaccine aids in the reduction of gross and microscopic lesions, tissue colonization, and fecal shedding of L. intracellularis in vaccinated pigs compared to non-vaccinated pigs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Claims (9)

  1. Vaccin vivant pour l'immunisation d'un animal, comprenant une quantité pharmaceutiquement efficace d'un isolat vivant avirulent de Lawsonia intracellularis et un vecteur pharmaceutiquement acceptables, dans lequel ledit isolat vivant avirulent est l'isolat de dépôt de Lawsonia intracellularis ATCC n°. PTA-4926 ou tout isolat vivant avirulent de Lawsonia intracellularis d'origine européenne, caractérisé en ce que ledit Lawsonia intracellularis vivant avirulent ne provoque pas d'élimination fécale le jour 14 après la vaccination.
  2. Vaccin vivant selon la revendication 1 dans lequel la quantité pharmaceutiquement efficace de l'isolat vivant avirulent de Lawsonia intracellularis est 103 TCID50 à 106 TCID50 par dose.
  3. Vaccin vivant pour l'immunisation d'un animal, comprenant un isolat vivant avirulent de Lawsonia intracellularis et une substance antigénique issue d'au moins l'un des pathogènes suivants : Salmonella spp., Erysipelothrix spp., Haemophilus spp., Mycoplasma spp., Leptospira spp., Clostridium spp., Streptococcus spp., Brachyspira spp., le circovirus, le virus du syndrome dysgénésique et respiratoire porcin (PRRS), le virus de la grippe porcine (SIV), le virus de gastro-entérite transmissible (TGE), le parvovirus, et Escherichia coli ; et un vecteur pharmaceutiquement acceptable, dans lequel ledit isolat vivant avirulent est l'isolat de dépôt de Lawsonia intracellularis ATCC n°. PTA-4926 ou tout isolat vivant avirulent de Lawsonia intracellularis d'origine européenne, caractérisé en ce que ledit Lawsonia intracellularis vivant avirulent ne provoque pas d'élimination fécale le jour 14 après la vaccination.
  4. Vaccin vivant pour l'immunisation d'un animal, comprenant un isolat vivant avirulent de Lawsonia intracellularis et une substance antigénique issue de Salmonella choleraesuis, Erysipelothrix spp., virus de gastro-entérite transmissible (TGE), Escherichia coli, Clostridium spp., et Brachyspira spp. ; et un vecteur pharmaceutiquement acceptable, dans lequel ledit isolat vivant avirulent est l'isolat de dépôt de Lawsonia intracellularis ATCC n°. PTA-4926 ou tout isolat vivant avirulent de Lawsonia intracellularis d'origine européenne, caractérisé en ce que ledit Lawsonia intracellularis vivant avirulent ne provoque pas d'élimination fécale le jour 14 après la vaccination.
  5. Vaccin vivant pour l'immunisation d'un animal, comprenant un isolat vivant avirulent de Lawsonia intracellularis et une substance antigénique issue de Salmonella choleraesuis et Erysipelothrix spp. ; et un vecteur pharmaceutiquement acceptable, dans lequel ledit isolat vivant avirulent est l'isolat de dépôt de Lawsonia intracellularis ATCC n°. PTA-4926 ou tout isolat vivant avirulent de Lawsonia intracellularis d'origine européenne, caractérisé en ce que ledit Lawsonia intracellularis vivant avirulent ne provoque pas d'élimination fécale le jour 14 après la vaccination.
  6. Vaccin vivant pour l'immunisation d'un animal, comprenant un isolat vivant avirulent de Lawsonia intracellularis et une substance antigénique issue d'au moins l'un des pathogènes suivants : Clostridium spp., le virus de la grippe équine (EIV), l'herpèsvirus équin (EHV), l'alphavirus, et le virus West Nile ; et un vecteur pharmaceutiquement acceptable, dans lequel ledit isolat vivant avirulent est l'isolat de dépôt de Lawsonia intracellularis ATCC n°. PTA-4926 ou tout isolat vivant avirulent de Lawsonia intracellularis d'origine européenne, caractérisé en ce que ledit Lawsonia intracellularis vivant avirulent ne provoque pas d'élimination fécale le jour 14 après la vaccination.
  7. Isolat vivant avirulent de Lawsonia intracellularis destiné à être utilisé comme vaccin, dans lequel ledit isolat vivant avirulent est l'isolat de dépôt de Lawsonia intracellularis ATCC n°. PTA-4926 ou tout isolat vivant avirulent de Lawsonia intracellularis d'origine européenne, caractérisé en ce que ledit Lawsonia intracellularis vivant avirulent ne provoque pas d'élimination fécale le jour 14 après la vaccination.
  8. Isolat vivant avirulent de Lawsonia intracellularis selon la revendication 7 destiné à être utilisé comme vaccin pour protéger un animal contre l'entéropathie proliférative porcine.
  9. Procédé pour produire un vaccin vivant pour induire une réponse immunitaire à des bactéries Lawsonia intracellularis chez un animal, comprenant les étapes de :
    (a) incuber un isolat vivant avirulent de Lawsonia intracellularis dans des cellules en culture qui sont en suspension à une concentration en oxygène inférieure à 10 pour cent pour cultiver lesdites bactéries, dans lequel ledit isolat vivant avirulent est l'isolat de dépôt de Lawsonia intracellularis ATCC n°. PTA-4926 ou tout isolat vivant avirulent de Lawsonia intracellularis d'origine européenne, caractérisé en ce que ledit Lawsonia intracellularis vivant avirulent ne provoque pas d'élimination fécale le jour 14 après la vaccination ; et
    (b) mélanger lesdites bactéries cultivées avec un vecteur pharmaceutiquement acceptable.
EP04778282.6A 2003-07-25 2004-07-15 Lawsonia intracellularis d'origine europeenne, vaccins, agents diagnostiques et procedes d'utilisation de ceux-ci Expired - Lifetime EP1651260B2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SI200431296T SI1651260T2 (sl) 2003-07-25 2004-07-15 Lawsonia intracellularis evropskega izvora in vakcine, diagnostična sredstva in postopki za njihovo uporabo
PL04778282T PL1651260T5 (pl) 2003-07-25 2004-07-15 Lawsonia intracellularis pochodzenia europejskiego oraz szczepionki, środki diagnostyczne i sposoby ją wykorzystujące
CY20091101223T CY1109652T1 (el) 2003-07-25 2009-11-25 Lawsonia intracellularis ευρωπαϊκης προελευσεως και εμβολια, διαγνωστικοι παραγοντες και μεθοδοι χρησεως τους

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49000103P 2003-07-25 2003-07-25
PCT/US2004/022704 WO2005011731A1 (fr) 2003-07-25 2004-07-15 Lawsonia intracellularis d'origine europeenne, vaccins, agents diagnostiques et procedes d'utilisation de ceux-ci

Publications (3)

Publication Number Publication Date
EP1651260A1 EP1651260A1 (fr) 2006-05-03
EP1651260B1 EP1651260B1 (fr) 2009-09-09
EP1651260B2 true EP1651260B2 (fr) 2018-06-27

Family

ID=34115340

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04778282.6A Expired - Lifetime EP1651260B2 (fr) 2003-07-25 2004-07-15 Lawsonia intracellularis d'origine europeenne, vaccins, agents diagnostiques et procedes d'utilisation de ceux-ci

Country Status (23)

Country Link
US (2) US7312065B2 (fr)
EP (1) EP1651260B2 (fr)
JP (1) JP2006528882A (fr)
KR (1) KR101131845B1 (fr)
CN (2) CN1829529B (fr)
AT (1) ATE442163T2 (fr)
AU (1) AU2004260657B2 (fr)
BR (1) BRPI0412911B1 (fr)
CA (1) CA2533559C (fr)
CY (1) CY1109652T1 (fr)
DE (1) DE602004023094D1 (fr)
DK (1) DK1651260T4 (fr)
ES (1) ES2333334T5 (fr)
MX (1) MXPA06000994A (fr)
MY (1) MY140208A (fr)
PL (1) PL1651260T5 (fr)
PT (1) PT1651260E (fr)
RU (1) RU2420570C2 (fr)
SG (1) SG144909A1 (fr)
SI (1) SI1651260T2 (fr)
UA (1) UA87665C2 (fr)
WO (1) WO2005011731A1 (fr)
ZA (1) ZA200510081B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022020593A3 (fr) * 2020-07-24 2022-02-24 Boehringer Ingelheim Animal Health USA Inc. Vaccin porcin combiné

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
AU2012207016B2 (en) * 2005-03-14 2015-01-15 Boehringer Ingelheim Animal Health USA Inc. Immunogenic compositions comprising Lawsonia intracellularis
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
US8398994B2 (en) * 2005-07-15 2013-03-19 Boehringer Ingelheim Vetmedica, Inc. Lawsonia vaccine and methods of use thereof
DK3320919T3 (da) 2005-12-29 2020-08-03 Boehringer Ingelheim Animal Health Usa Inc Multivalente pcv2-immunogeniske sammensætninger og fremgangsmåder til at fremstille sådanne sammensætninger
DK2371383T3 (en) * 2005-12-29 2015-11-30 Boehringer Ingelheim Vetmed Use of a PCV2 immunogenic composition for reduction of clinical symptoms in pigs
US8470336B2 (en) * 2006-05-25 2013-06-25 Boehringer Ingelheim Vetmedica, Inc. Vaccination of young animals against Lawsonia intracellularis infections
US20080241190A1 (en) * 2006-11-13 2008-10-02 Boehringer Ingelheim Vetmedica, Inc. Vaccination of horses against lawsonia intracellularis
EP2099927A4 (fr) * 2006-11-22 2010-05-05 Boehringer Ingelheim Vetmed Procedes de reduction des flambees des maladies associees au circovirus porcin
EP2859900A1 (fr) 2006-12-11 2015-04-15 Boehringer Ingelheim Vetmedica, Inc. Procédé efficace de traitement du circovirus porcin et des infections par lawsonia intracellularis
PL2094872T5 (pl) * 2006-12-15 2020-10-05 Boehringer Ingelheim Animal Health USA Inc. Leczenie świń seropozytywnych wobec przeciwciała anty-pcv2 antygenem pcv2
EP1941903A1 (fr) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxie et traitement du PRDC
EP1958644A1 (fr) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prévention et traitement du PCVD subclinique
US7829274B2 (en) * 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
CL2008002675A1 (es) * 2007-09-11 2008-11-07 Wyeth Corp Bacteria de mycoplasma gallisepticum atenuada; composicion de vacuna que la comprende; método de vacunación; y método de identificación de clones de mycoplasma gallisepticum atenuados.
EP2200643B1 (fr) 2007-09-17 2013-09-04 Boehringer Ingelheim Vetmedica, Inc. Un vaccin vivant de lawsonia intracellularis administré en association avec un antibiotique pour le traitement des infections de lawsonia intracellularis dans les porcs
JP2011508595A (ja) * 2007-12-31 2011-03-17 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド 外来性アミノ酸の挿入を含むｐｃｖ２ｏｒｆ２ウイルス様粒子
KR20100113582A (ko) 2008-01-23 2010-10-21 베링거잉겔하임베트메디카인코퍼레이티드 Ｐｃｖ2 마이코플라즈마 히오뉴모니에 면역원성 조성물 및 당해 조성물의 생산 방법
US20110033495A1 (en) * 2008-02-15 2011-02-10 Boehringer Ingelheim Vetmedica, Inc. Methods and compositions for reducing the impact of enteric diseases
TWI449533B (zh) * 2008-04-18 2014-08-21 Intervet Int Bv 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗
TWI551295B (zh) 2008-04-18 2016-10-01 英特威特國際股份有限公司 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）用疫苗
JP5723772B2 (ja) * 2008-07-22 2015-05-27 インターベット インターナショナル ベー． フェー． 新規血清型のローソニア・イントラセルラリス細菌、その細菌に基づくワクチン、該新規ローソニア・イントラセルラリス血清型の特定に適した抗体および該抗体を製造するためのハイブリドーマ
US8142760B2 (en) * 2008-09-05 2012-03-27 Nathan Len Winkelman Vaccination for Lawsonia intracellularis
WO2011006880A1 (fr) * 2009-07-14 2011-01-20 Intervet International B.V. Propagation de lawsonia intracellularis
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
US8530223B2 (en) 2009-11-09 2013-09-10 Intervet International B.V. Method to grow Lawsonia intracellularis bacteria in persistently infected McCoy cells
CA2793959C (fr) 2010-03-25 2019-06-04 Oregon Health & Science University Glycoproteines du cmv et vecteurs recombines
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
CN105579060B (zh) 2013-09-25 2021-03-16 硕腾服务有限责任公司 Pcv2b趋异株疫苗组合物以及使用方法
AU2014329524B2 (en) 2013-10-02 2019-01-17 Boehringer Ingelheim Animal Health USA Inc. PCV2 ORF2 protein variant and virus like particles composed thereof
RU2672251C1 (ru) * 2013-12-03 2018-11-13 Интервет Интернэшнл Б.В. Вакцина против lawsonia intracellularis и свиного цирковируса 2-го типа
CN103823063B (zh) * 2014-02-25 2015-09-30 上海理工大学 检测猪霍乱沙门氏菌的方法及其单抗
WO2016124623A1 (fr) 2015-02-04 2016-08-11 Intervet International B.V. Vaccin pouvant être utilisé contre une infection subclinique à lawsonia chez le porc
KR101893827B1 (ko) * 2016-01-04 2018-08-31 전북대학교 산학협력단 약독화된 살모넬라 변이주를 유효성분으로 포함하는 돼지 증식성 회장염 및 살모넬라증 동시 예방 또는 치료용 백신 조성물
AU2019228294A1 (en) 2018-02-28 2020-08-13 Boehringer Ingelheim Vetmedica Gmbh Method for reducing skatole and/or indole in animals
KR102249189B1 (ko) * 2020-01-09 2021-05-07 전북대학교 산학협력단 항원성이 증진된 항원을 발현하는 약독화된 살모넬라 변이주를 유효성분으로 포함하는 돼지 증식성 회장염 및 살모넬라증 동시 예방 또는 치료용 백신 조성물
CN111961627A (zh) * 2020-08-27 2020-11-20 南京农业大学 一种胞内劳森菌的分离与培养方法
US20230141226A1 (en) 2021-11-01 2023-05-11 Boehringer Ingelheim Vetmedica Gmbh Immunogenic gel compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039629A1 (fr) † 1995-06-05 1996-12-12 Boehringer Ingelheim/Nobl Laboratories, Inc. Culture de lawsonia intracellularis, vaccin contre lawsonia intracellularis et agents de diagnostic

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714375A (en) * 1995-06-05 1998-02-03 Nobl Laboratories, Inc. Ileal symbiont intracellularis propagation in suspended host cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039629A1 (fr) † 1995-06-05 1996-12-12 Boehringer Ingelheim/Nobl Laboratories, Inc. Culture de lawsonia intracellularis, vaccin contre lawsonia intracellularis et agents de diagnostic
EP0843818B1 (fr) † 1995-06-05 2005-02-09 Boehringer Ingelheim Vetmedica, Inc. Culture de lawsonia intracellularis, vaccin contre lawsonia intracellularis et agents de diagnostic

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GEBHART C.J. ET AL: "Ileal symbiont intracellularis, an obligate intracellular bacterium of porcine inteestines showing a relationship to Desulfovibrio Species", INT.JOUR. OF SYSTEMATIC BACTERIOLOGY, July 1993 (1993-07-01), pages 533 - 538, XP008100964 †
KNITTEL J.P. ET AL: "United States isolates of Lawsonia intracellularis from porcine proliferative entropathy resemble European isolates", SWINE HEALTH AND PRODUCTION, vol. 4, no. 3, 1996, pages 119 - 122 †
MCORIST S. ET AL: "Reproduction of porcine proliferative enteropathy with pure cultures of ileal symbiont intracellularis", INFECTION AND IMMUNITY, October 1993 (1993-10-01), pages 4286 - 4292 †

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022020593A3 (fr) * 2020-07-24 2022-02-24 Boehringer Ingelheim Animal Health USA Inc. Vaccin porcin combiné

Also Published As

Publication number Publication date
EP1651260B1 (fr) 2009-09-09
ATE442163T2 (de) 2009-09-15
JP2006528882A (ja) 2006-12-28
ES2333334T3 (es) 2010-02-19
RU2420570C2 (ru) 2011-06-10
US20080112980A1 (en) 2008-05-15
CN1829529B (zh) 2011-05-04
SI1651260T2 (sl) 2018-09-28
CN101423811A (zh) 2009-05-06
RU2006105715A (ru) 2007-09-10
SG144909A1 (en) 2008-08-28
CA2533559C (fr) 2013-07-02
US7758870B2 (en) 2010-07-20
MY140208A (en) 2009-11-30
BRPI0412911A (pt) 2006-09-26
ZA200510081B (en) 2006-08-30
BRPI0412911B1 (pt) 2020-01-21
US20050031647A1 (en) 2005-02-10
US7312065B2 (en) 2007-12-25
CN1829529A (zh) 2006-09-06
AU2004260657B2 (en) 2012-06-07
KR101131845B1 (ko) 2012-03-30
WO2005011731A1 (fr) 2005-02-10
AU2004260657A1 (en) 2005-02-10
CY1109652T1 (el) 2014-08-13
DK1651260T4 (en) 2018-10-08
SI1651260T1 (sl) 2010-01-29
PL1651260T5 (pl) 2018-11-30
KR20060054352A (ko) 2006-05-22
EP1651260A1 (fr) 2006-05-03
DE602004023094D1 (de) 2009-10-22
ES2333334T5 (es) 2018-08-06
DK1651260T3 (da) 2010-01-11
CA2533559A1 (fr) 2005-02-10
PT1651260E (pt) 2009-09-24
PL1651260T3 (pl) 2010-02-26
UA87665C2 (ru) 2009-08-10
MXPA06000994A (es) 2006-05-15

Similar Documents

Publication Publication Date Title
EP1651260B2 (fr) Lawsonia intracellularis d'origine europeenne, vaccins, agents diagnostiques et procedes d'utilisation de ceux-ci
EP1403643B2 (fr) Cultivation de Lawsonia intracellularis, vaccins anti-lawsonia et agents de diagnostique
CN1519311B (zh) 胞内劳森氏菌培养、抗该菌的疫苗和诊断试剂
MXPA97009464A (en) Culture of lawsonia intracellularis, vaccines against lawsonia intracellulares and agents of diagnost

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060227

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: LV

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20060227

17Q First examination report despatched

Effective date: 20070614

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: LV

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20090918

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602004023094

Country of ref document: DE

Date of ref document: 20091022

Kind code of ref document: P

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20090402680

Country of ref document: GR

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E003776

Country of ref document: EE

Effective date: 20091127

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2333334

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E006977

Country of ref document: HU

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 6789

Country of ref document: SK

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: INTERVET INTERNATIONAL B.V.

Effective date: 20100521

26 Opposition filed

Opponent name: PFIZER, INC.

Effective date: 20100608

Opponent name: INTERVET INTERNATIONAL B.V.

Effective date: 20100521

PLBP Opposition withdrawn

Free format text: ORIGINAL CODE: 0009264

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

PLCK Communication despatched that opposition was rejected

Free format text: ORIGINAL CODE: EPIDOSNREJ1

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

APBQ Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3O

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: INTERVET INTERNATIONAL B.V.

Effective date: 20100521

PLAY Examination report in opposition despatched + time limit

Free format text: ORIGINAL CODE: EPIDOSNORE2

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PLBC Reply to examination report in opposition received

Free format text: ORIGINAL CODE: EPIDOSNORE3

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

27A Patent maintained in amended form

Effective date: 20180627

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: LV

REG Reference to a national code

Ref country code: DE

Ref legal event code: R102

Ref document number: 602004023094

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: ES

Ref legal event code: DC2A

Ref document number: 2333334

Country of ref document: ES

Kind code of ref document: T5

Effective date: 20180806

REG Reference to a national code

Ref country code: EE

Ref legal event code: LD4A

Ref document number: E003776

Country of ref document: EE

REG Reference to a national code

Ref country code: SK

Ref legal event code: T5

Ref document number: E 6789

Country of ref document: SK

REG Reference to a national code

Ref country code: SE

Ref legal event code: RPEO

REG Reference to a national code

Ref country code: DK

Ref legal event code: T4

Effective date: 20181001

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20180402504

Country of ref document: GR

Effective date: 20190225

REG Reference to a national code

Ref country code: EE

Ref legal event code: HC1A

Ref document number: E003776

Country of ref document: EE

REG Reference to a national code

Ref country code: NL

Ref legal event code: PD

Owner name: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.; US

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), MERGE; FORMER OWNER NAME: BOEHRINGER INGELHEIM VETMEDICA, INC.

Effective date: 20190607

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.

Effective date: 20190718

REG Reference to a national code

Ref country code: HU

Ref legal event code: GB9C

Owner name: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC., US

Free format text: FORMER OWNER(S): BOEHRINGER INGELHEIM VETMEDICA, INC., US

REG Reference to a national code

Ref country code: SI

Ref legal event code: SP73

Owner name: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.; US

Effective date: 20190719

REG Reference to a national code

Ref country code: SK

Ref legal event code: TC4A

Ref document number: E 6789

Country of ref document: SK

Owner name: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC., D, US

Effective date: 20191104

REG Reference to a national code

Ref country code: BE

Ref legal event code: HC

Owner name: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.; US

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME

Effective date: 20210118

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 442163

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180627

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230509

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20230623

Year of fee payment: 20

Ref country code: NL

Payment date: 20230719

Year of fee payment: 20

Ref country code: LU

Payment date: 20230719

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230713

Year of fee payment: 20

Ref country code: RO

Payment date: 20230711

Year of fee payment: 20

Ref country code: MC

Payment date: 20230724

Year of fee payment: 20

Ref country code: IT

Payment date: 20230724

Year of fee payment: 20

Ref country code: IE

Payment date: 20230719

Year of fee payment: 20

Ref country code: GB

Payment date: 20230719

Year of fee payment: 20

Ref country code: FI

Payment date: 20230719

Year of fee payment: 20

Ref country code: ES

Payment date: 20230926

Year of fee payment: 20

Ref country code: EE

Payment date: 20230717

Year of fee payment: 20

Ref country code: CZ

Payment date: 20230711

Year of fee payment: 20

Ref country code: CY

Payment date: 20230622

Year of fee payment: 20

Ref country code: CH

Payment date: 20230802

Year of fee payment: 20

Ref country code: BG

Payment date: 20230719

Year of fee payment: 20

Ref country code: AT

Payment date: 20230720

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20230710

Year of fee payment: 20

Ref country code: SI

Payment date: 20230706

Year of fee payment: 20

Ref country code: SE

Payment date: 20230719

Year of fee payment: 20

Ref country code: PT

Payment date: 20230706

Year of fee payment: 20

Ref country code: HU

Payment date: 20230721

Year of fee payment: 20

Ref country code: GR

Payment date: 20230721

Year of fee payment: 20

Ref country code: FR

Payment date: 20230725

Year of fee payment: 20

Ref country code: DK

Payment date: 20230721

Year of fee payment: 20

Ref country code: DE

Payment date: 20230719

Year of fee payment: 20

Ref country code: BE

Payment date: 20230719

Year of fee payment: 20

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20240714

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Expiry date: 20240715

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240715

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20240729

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240715

REG Reference to a national code

Ref country code: BE

Ref legal event code: MK

Effective date: 20240715

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20240714

REG Reference to a national code

Ref country code: SK

Ref legal event code: MK4A

Ref document number: E 6789

Country of ref document: SK

Expiry date: 20240715

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 442163

Country of ref document: AT

Kind code of ref document: T

Effective date: 20240715

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240715

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240724

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240714

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240716

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240715

Ref country code: SI

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240716

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240715

Ref country code: SI

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240716

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240724

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240715

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240714

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240716

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载